ai cancer platform News
-
Prognos Health and xCures Partner to enable Access to Real World Oncology Datasets
Today, at the annual meeting of the American Society of Clinical Oncology (ASCO), Prognos Health and xCures announced a collaboration to enable real-world data access and insights for life science companies across multiple use cases. The multi-year agreement will enable linking and access to xCures de-identified data and Prognos healthcare data marketplace. “We are excited about combining ...
By xCures
-
xCures and Novocure partner to better understand quality of life in glioblastoma
xCures, Inc., is proud to announce their partnership with Novocure with the intent to develop the first comprehensive, longitudinal Quality of Life (QoL) dataset for glioblastoma (GBM) patients. The alliance between both oncology companies will leverage xCures’ novel, patient-centric platform and deep connections to GBM patient and provider communities through direct engagement with GBM ...
By xCures
-
xCures partners with Travera to support advanced carcinoma patients and their physicians
xCures, Inc. is proud to announce their partnership with Travera, and the launch of a decentralized clinical trial that provides patients with advanced carcinoma a functional profile of their cancer cells. Advanced carcinoma patients often have malignant fluid drained to provide symptomatic relief. Travera’s unique technology takes advantage of this fluid to screen the response of the live ...
By xCures
-
xCures and mProbe partner to help cancer patients determine optimal treatments
xCures, Inc. is proud to announce their collaboration with mProbe Inc., a premier CLIA-certified targeted proteomics company. mProbe utilizes a proprietary technology platform integrating artificial intelligence and multi-omic diagnostics to transform the diagnosis, prevention, and treatment of complex diseases such as cancer. As the knowledge of cancer and its treatments advance, it is ever ...
By xCures
-
Pancreatic Cancer Patients Will Now Have Remote Access to Precision Nutrition Trial Through New Partnership
xCures, Inc. is proud to partner with Vault Health, a decentralized research and workforce screening company, to facilitate the enrollment of pancreatic cancer patients in Faeth Therapeutics’ NEAAR-001 research study. NEAAR-001 is a clinical trial of a precision nutrition-based diet that restricts specific amino acids that preclinical studies suggest are necessary for cancer growth. The ...
By xCures
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you